<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/19/3297722/32716/en/Erasca-Inc-ERAS-Shares-Crater-48-Wiping-Out-2-8-Billion-of-Market-Cap-Hagens-Berman-Investigating-Intellectual-Property-Questions-Regarding-Lead-Asset.html">Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015). The challenge is being waged by competitor Revolution Medicines (RevMed) and relates to RevMed&#39;s RMC-6...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/15/3295509/937/en/ERAS-SHAREHOLDER-ALERT-Investors-Encouraged-to-Contact-Kirby-McInerney-LLP-About-Potential-Securities-Laws-Violations.html">ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of  Kirby McInerney LLP reminds investors of its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company&#39;s and/or members of its senior management&#39;s possible violation of the federal securities laws or other unlawful business practices.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/14/3295477/0/en/ERASCA-INVESTOR-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Erasca-Inc-on-Behalf-of-Erasca-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html">ERASCA INVESTOR ALERT: Bragar Eagel &amp; Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm</a>
    </div>

      <div class="me-0 me-md-5">
        Bragar Eagel &amp; Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260512000222/en/ERASCA-INC.-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud/">ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On Apr...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/11/3292285/0/en/Erasca-Reports-First-Quarter-2026-Business-Updates-and-Financial-Results.html">Erasca Reports First Quarter 2026 Business Updates and Financial Results</a>
    </div>

      <div class="me-0 me-md-5">
        Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/11/3291730/0/en/Erasca-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Merck-to-Evaluate-ERAS-0015-in-Combination-with-KEYTRUDA-Pembrolizumab.html">Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)</a>
    </div>

      <div class="me-0 me-md-5">
        ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/06/3288785/0/en/erasca-to-present-at-the-bank-of-america-securities-health-care-conference.html">Erasca to Present at the Bank of America Securities Health Care Conference</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Man...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Erasca-Inc-US29479A1088">Erasca Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/04/3287243/23044/en/Erasca-Inc-Investors-Should-Contact-Block-Leviton-LLP-to-Learn-More-About-Securities-Fraud-Investigation.html">Erasca, Inc. Investors Should Contact Block &amp; Leviton LLP to Learn More About Securities Fraud Investigation</a>
    </div>

      <div class="me-0 me-md-5">
        Investors who lost money in Erasca Inc. (Nasdaq: $ERAS) should contact Block &amp; Leviton to potentially recover losses via securities fraud investigation.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Erasca-Inc-US29479A1088/load_more?page=4">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>